Reply to Garg et al, Smith et al, and Persichino and Miller.

Nash, Theodore E.; García Lescano, Héctor Hugo; Rajshekhar, Vedantam; Mohanty, Aaron; Hauser, W. Allen; Singh, Gagandeep; White, A. Clinton Jr; Coyle, Christina M.

dc.contributor.author	White, A. Clinton Jr
dc.contributor.author	Coyle, Christina M.
dc.contributor.author	Rajshekhar, Vedantam
dc.contributor.author	Singh, Gagandeep
dc.contributor.author	Hauser, W. Allen
dc.contributor.author	Mohanty, Aaron
dc.contributor.author	García Lescano, Héctor Hugo
dc.contributor.author	Nash, Theodore E.
dc.date.accessioned	2019-03-05T15:25:02Z
dc.date.available	2019-03-05T15:25:02Z
dc.date.issued	2018
dc.identifier.uri	https://hdl.handle.net/20.500.12866/5926
dc.description.abstract	We thank Garg and colleagues for their letter. Two randomized trials compared albendazole and combination therapy with simultaneous praziquantel and albendazole. In both cases, the radiologic response was better with combination therapy only in patients with >2 viable parenchymal cysts but not in those with ≤2 cysts. These trials were the basis for the distinction in treatment of viable parenchymal disease distinguishing patients with 1 or 2 parenchymal cysts form those with ≥3 parenchymal cysts or viable parenchymal cysticercosis. However, neither of these trials included patients with >20 cysticerci.	en_US
dc.language.iso	eng
dc.publisher	Oxford University Press
dc.relation.ispartofseries	Clinical Infectious Diseases
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject	Correspondence	en_US
dc.title	Reply to Garg et al, Smith et al, and Persichino and Miller.	en_US
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	https://doi.org/10.1093/cid/ciy437
dc.subject.ocde	https://purl.org/pe-repo/ocde/ford#3.03.08
dc.relation.issn	1537-6591